Discover this podcast and so much more

Podcasts are free to enjoy without a subscription. We also offer ebooks, audiobooks, and so much more for just $11.99/month.

TRIM63 as a biomarker for MiT family RCC

TRIM63 as a biomarker for MiT family RCC

FromModPath Chat


TRIM63 as a biomarker for MiT family RCC

FromModPath Chat

ratings:
Length:
21 minutes
Released:
Aug 3, 2021
Format:
Podcast episode

Description

In this episode Dr. Rohit Mehra of University of Michigan discusses the utility of TRIM63 as a diagnostic marker to distinguish MiTF-RCC from other renal tumor subtypes with overlapping morphology. In combination with TFE3/TFEB FISH, TRIM63 RNA-ISH assays can improve the accuracy and efficiency of MiTF-RCC diagnosis.Study by Mehra et al, TRIM63 is a sensitive and specific biomarker for MiT family aberration-associated renal cell carcinoma. Modern Pathology, 34, 1596-1607, 2021. https://www.nature.com/articles/s41379-021-00803-z. Our GDPR privacy policy was updated on August 8, 2022. Visit acast.com/privacy for more information.
Released:
Aug 3, 2021
Format:
Podcast episode

Titles in the series (58)

ModPath Chat is the official podcast of Modern Pathology, the journal of the US and Canadian Academy of Pathology (USCAP). ModPath Chat features interviews with authors, opinion leaders and experts on the latest science, technology, and developments in the field of pathology. The monthly podcast series is hosted by Dr. George J. Netto, the Editor-in-Chief of Modern Pathology and the Chair of Pathology at the University of Alabama in Birmingham Our GDPR privacy policy was updated on August 8, 2022. Visit acast.com/privacy for more information.